It is known that Huntington’s Disease (HD) is caused by the expression of a mutated form of the Huntingtin protein containing a polyglutamine (polyQ) repeat, with the length of the repeat correlating to increased severity of the disease. Since concentrations of total and mutant HTT in premanifest and controls groups are extremely low, it is imperative the assays are able to reach fM levels of sensitivity. Employing SMC® technology we are able to provide the HD community with tools to enable better understanding of the disease and to assist in the development of new therapeutics. During this webinar we will review data from the development and validation of the High Sensitivity SMC® Immunoassays for the Quantification of mHTT and total HTT.
For Research Use Only. Not For Use In Diagnostic Procedures.
Speaker
Sarah Hamren
Merck
Former Head of Custom Assays & Sample Testing Group
Sarah Hamren was the former head of the SMC® Custom Assay and Sample Testing group until 2021. She has over 30 years of experience in biopharma research and development and her past experience includes work at Chiron Corporation, Bayer Corporation’s Biotechnology division, Tethys Bioscience, and Singulex® Inc. before joining us. She is co-author on 15 peer-reviewed publications and holds 2 U.S. patents. Sarah’s experience effectively partnering with a broad array of clients has culminated in hundreds of successful biomarker assay development projects.
Protein biology
- Protein quantitation
Duración:48min
Idioma:English
Sesión 1:presentado December 10, 2019
Para seguir leyendo, inicie sesión o cree una cuenta.
¿No tiene una cuenta?